A5011558600- Renal Diseases and Glomerulopathies
- Immunotherapy and Immune Responses
- Diabetes Treatment and Management
- Electrolyte and hormonal disorders
- Complement system in diseases
- T-cell and B-cell Immunology
- Multiple Myeloma Research and Treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Reproductive System and Pregnancy
- Toxin Mechanisms and Immunotoxins
- Cancer, Lipids, and Metabolism
- Ubiquitin and proteasome pathways
- Vasculitis and related conditions
- Diabetes and associated disorders
- Cancer, Hypoxia, and Metabolism
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Cholesterol and Lipid Metabolism
- Nitric Oxide and Endothelin Effects
- Pharmacology and Obesity Treatment
- Metabolism and Genetic Disorders
- Hemoglobinopathies and Related Disorders
- Birth, Development, and Health
- Hormonal Regulation and Hypertension
- Pregnancy and preeclampsia studies
- Eosinophilic Disorders and Syndromes
Harvard University
2015-2024
Beth Israel Deaconess Medical Center
2020-2024
Lahey Medical Center
2023
Brigham and Women's Hospital
2015-2018
Despite significant advances in the treatment of multiple myeloma (MM), most patients succumb to disease progression. One major immunosuppressive mechanisms that is believed play a role progression expansion regulatory T cells (Tregs). In this study, we demonstrate drive Treg and activation by secreting type 1 interferon (IFN). Blocking IFN α β receptor (IFNAR1) on Tregs significantly decreases both myeloma-associated function Using syngeneic transplantable murine models bone marrow (BM)...
Significance The potential of proteasome inhibitors to prevent transplant rejection and treat other immune disorders is hindered by mechanism-based toxicity from inhibition constitutive proteasomes. Here, we demonstrate that briefly, reversibly, selectively inhibiting the immunoproteasome prolonged survival transplanted hearts in mice allowed long-term when combined with single-dose CTLA4-Ig. Immunoproteasome noncytotoxically reduced T-cell proliferation numbers effector T cells allograft...
Tregs hold great promise as a cellular therapy for multiple immunologically mediated diseases, given their ability to control immune responses. The success of such strategies depends on the expansion healthy, suppressive ex vivo and in following transfer. In clinical studies, levels transferred decline sharply blood within few days have high rate apoptosis. Here, we describe new mechanism Treg self-inflicted damage. We show that granzymes A -B (GrA GrB), which are highly upregulated human...
Background: Preeclampsia (PE) is a hypertensive disorder of pregnancy that associated with substantial morbidity and mortality for the mother fetus. Reduced nitric oxide bioavailability oxidative stress contribute to maternal fetal pathophysiology PE. In this study, we evaluated efficacy novel dual-function donor/redox modulator, AKT-1005, in reducing PE symptoms mouse model Method: The potential therapeutic effect AKT-1005 was tested an animal Ad.sFlt-1-induced hypertension, proteinuria...
gomes, Larissa Kruger; Karreci, Esilida Sula; Agarwal, Krishna A.; Schulman, Ruth; William, Jeffrey H.; Lecker, Stewart Stillman, Isaac E. Author Information
Karreci, Esilida Sula; Zsengeller, Zsuzsanna K.; Friedman, David; Alper, Seth L.; Pollak, Martin Author Information
Karreci, Esilida Sula; gomes, Larissa Kruger; Schulman, Ruth; Agarwal, Krishna A.; Pandit, Amar; Denker, Bradley M.; Beth Israel Deaconess Author Information
Agarwal, Krishna A.; Karreci, Esilida Sula; gomes, Larissa Kruger; Schulman, Ruth; Stillman, Isaac E.; Lecker, Stewart H.; Steinman, Theodore I.; Denker, Bradley M.; BIDMC Author Information
Agarwal, Krishna A.; gomes, Larissa Kruger; Karreci, Esilida Sula; Schulman, Ruth; Heher, Yael K.; Denker, Bradley M.; BIDMC Author Information
Schulman, Ruth; gomes, Larissa Kruger; Agarwal, Krishna A.; Karreci, Esilida Sula; Freed, Jason Hoenig, Melanie P. Author Information